Treatment of Idiopathic Membranous Nephropathy

Meryl Waldman and Howard A. Austin III

Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

ABSTRACT

Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone, with an emphasis on results of the most recent clinical trials.


This is an especially exciting time in the history of idiopathic membranous nephropathy (IMN). Our understanding of its natural history and pathogenetic mechanisms has been slowly evolving over several decades but has recently gained more momentum. This, in conjunction with data from recent clinical trials, makes it an ideal time to revisit our approach to patients with IMN.

The recent identification of the M-type phospholipase A2 receptor (PLA2R) as the first major human antigenic target in adult onset IMN represents a major milestone in understanding of the pathogenesis of this disease. In 2009, Beck et al. reported that the majority of IMN patients (70%) have circulating antibodies against PLA2R, a cell surface transmembrane receptor expressed on the surface of podocytes.1 Compelling work from Beck et al. suggests that the subepithelium-like deposits, characteristic of IMN, are formed from in situ binding of circulating anti-PLA2R autoantibodies to the PLA2R antigen. From a historical perspective, the findings of Beck et al. come 50 years after Heymann et al. first described an experimental model of membranous disease known as Heymann nephritis by injecting rats with an antigenic preparation of kidney extracts.2 Elegant work over several decades on this now well established rat model shed light on the immune events and molecular basis for podocyte injury in membranous lesions and generated hypotheses regarding their relevance in human disease.3–5 Indeed, the findings of Beck et al. are in agreement with a critical prediction of the Heymann model that circulating autoantibodies directed against a podocyte moity cause IMN.

The precise biologic function of PLA2R in the kidney and the effect of anti-PLA2R on podocytes are still unknown.6 However, the existing body of evidence supports the following important concepts: autoantibodies reactive to PLA2R are both sensitive and specific for the disease;6,7 autoantibodies seem to discriminate between primary and secondary forms of membranous disease,1 and there seems to be a relationship (in most, but not all patients) between the titer of circulating anti-PLA2R and clinical disease activity defined by proteinuria.8,9 Moreover, changes in titers of anti-PLA2R antibody precede corresponding changes in proteinuria.10,11 These observations strengthen the relevance of this antigen-autoantibody pair in IMN. However, it is important to note that causation has yet to be definitively proven.12

Additional podocyte autoantigens including SOD2,16 aldose reductase,16 α-enolase,17 and neutral endopeptidase18 are also implicated as targets for specific autoantibodies in some IMN patients. Antibodies to these targets may be relevant in patients who are negative for PLA2R antibody. Unlike the anti-PLA2R antibody, correlation of antibody titers for these antigens with disease activity has not been reported to date.

What incites the immune response and triggers the development of these and other autoantibodies remain a mystery.19 Genetics may play a role. Results of a recent genome-wide association study in a large European cohort suggest that sequence variants within HLA-DQA1 and PLA2R1 alleles might confer an increased risk of membranous nephropathy in some populations.20

We have only touched the tip of the iceberg, and there is still so much to learn. Nevertheless, what has been uncovered thus far is certainly provocative and will advance our approach to diagnosis, monitoring, and treatment of patients with membranous nephropathy.
This disease in the near future. Application of new technology is allowing for a much faster transition of these bench–side findings to the bedside, and progress has already been made in developing standardized immunoassays for anti-PLA2R for use in clinical practice. One can envision how integrating information obtained from genetic testing and antigen-antibody profiling might potentially be applied for individual patient management and in future clinical trials in that it may help to better classify subsets of patients with different prognoses or to predict response to treatment. Measurement of circulating anti-PLA2R and other antibodies may be used in conjunction with proteinuria to better assess disease activity and provide a more informative definition of clinical remission. Such information might provide insight as to whether persistent proteinuria in patients is related to ongoing immunologic activity, amenable to more immunosuppression, or due to fixed structural damage to glomeruli or tubulointerstitium. Future clinical trials might use such information to identify and enroll a more homogenous population of patients at higher risk of disease progression who would most benefit from immunosuppression. In addition, comparison of efficacy of immunosuppressive agents in trials might involve evaluation of their effect on immune activity, including the timing and kinetics of autoantibody clearance from the circulation.

**NATURAL HISTORY OF IMN**

As we move forward in our understanding of the pathogenesis of disease in IMN, two recent studies re-examine more basic concepts regarding the natural history of IMN. These concepts were largely derived from studies performed 2–3 decades ago, when antiproteinuric strategies and other supportive measures were implemented inconsistently. Moreover, some of the older studies included patients with non-nephrotic–range proteinuria, a group with an invariably good prognosis. In contrast, these contemporary studies include only nephrotic patients, make greater use of antiproteinuric strategies, and serve as important references to inform management decisions in these patients.

An impressive multicenter study from the Spanish Group for the Study of Glomerular Disease (GLOSEN) examined the course of a large number of nephrotic IMN patients (n=328) who were diagnosed between 1975 and 2007 and followed for an extended period of time (approximately 6 years). Importantly, because of the possibility of spontaneous remission, all patients were initially managed conservatively; immunosuppressive therapy was withheld until complications arose or deterioration of renal function was evident, an approach that provides greater insight into the natural evolution of this disease. Approximately two-thirds of patients received angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Almost 32% of patients experienced a spontaneous remission, most of which occurred within the first 2 years of diagnosis, comparable with several other studies.

Two features regarding spontaneous remissions in the Spanish study deserve consideration. First, among patients destined to experience a spontaneous remission, proteinuria tended to decline gradually. Moreover, a decrease in proteinuria during the first year of follow-up >50% of baseline (even if still nephrotic) significantly predicted spontaneous remission. Second, spontaneous remissions were observed among some high-risk patients, including approximately 25% of those with severe proteinuria (>8 g/24 h) as well as a number of patients with CKD, another subset considered unlikely to undergo spontaneous remission. Consequently, careful observation of some high-risk patients may be appropriate before starting immunosuppressive therapy, particularly if they are not experiencing complications of the nephrotic syndrome or declining renal function and if they are manifesting a gradual decline in proteinuria.

Concordant with previous reports, the long-term outcome and renal survival of those with spontaneous remission (either complete or partial) is excellent, with a 0% risk of ESRD and a 2% mortality rate. In contrast, outcomes in patients who have persistence of nephrotic-range proteinuria are less favorable, with a 11% mortality rate and a 19% risk of ESRD.

A second contemporary natural history study from the United Kingdom by McQuarrie et al. analyzed patients diagnosed between 1997 and 2008. Almost all patients were treated with ACE inhibitors and/or ARBs. Consistent with the above data and previous reports, this study showed that achieving any remission (spontaneous or treatment-induced) independently associated with a reduced risk of requiring renal replacement therapy (hazard ratio, 0.02; 95% confidence interval, 0.0–0.2; P=0.001) and reduced risk of death (hazard ratio, 0.07; 95% confidence interval, 0.02–0.3; P=0.001).

Although these contemporary retrospective analyses do have greater implementation of ACE inhibitors or ARBs, they were not designed to formally evaluate whether these drugs have significant benefit on renal prognosis or reduction of proteinuria in IMN. Some investigators note that responsiveness to these agents is less impressive in IMN compared with other types of glomerular disorders, which has raised questions about their role in this disorder. In the GLOSEN study, the probability of spontaneous remission was higher in patients taking ACE inhibitors or ARBs than those not receiving these agents (P=0.009). In the study by McQuarrie et al. in which there was widespread use of ACE inhibitors/ARBs, the 5-year actuarial rate for spontaneous partial remission was remarkably high at 70%. These data hint, but do not prove, that ACE inhibitors and ARBs have favorable effects on the disease. In contrast, other studies failed to demonstrate an effect of ACE inhibitors on renal outcome in IMN. This issue cannot be definitively answered without a controlled trial. For now, given that treatment with ACE inhibitors and ARBs has proven benefits in other kidney diseases and may result in some improvement in proteinuria, hypalbuminemia, and hyperlipidemia, these agents should remain as part of standard conservative treatment for IMN.
**IMMUNOSUPPRESSION**

Immunosuppressive therapies that have received the most attention for IMN include alkylating agents such as cyclophosphamide and chlorambucil, calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus, mycophenolate mofetil (MMF), rituximab, and adrenocorticotropin hormone (ACTH). Table 1 shows the commonly used regimens, although many variations exist. There is a lack of well-powered, randomized, controlled trials that formally compare therapies. The quality of the existing evidence for these different regimens in IMN is variable. Comparisons among studies are hampered by differences in the risk profiles of the patients and variable duration of follow-up, among other factors.

**Alkylating Agents**

Table 2 depicts results of several studies examining the efficacy of two very different approaches to cytotoxic drug therapy for IMN. Ponticelli et al. and Jha et al. used a 6-month regimen consisting of daily oral chlorambucil or cyclophosphamide, alternating monthly with corticosteroids. Their patients had nephrotic-range proteinuria and normal or near normal renal function. Conversely, investigators from the Netherlands have described outcomes of an extended course, typically 12 months (Table 1), of daily oral cyclophosphamide and corticosteroids in patients with nephrotic syndrome and deteriorating renal function.

Both Ponticelli et al. and Jha et al. found that alternating monthly cycles of corticosteroids and an alkylating agent were more effective than supportive therapy alone for inducing remissions of proteinuria and preserving renal function. Ponticelli et al. found that substitution of cyclophosphamide for chlorambucil provides similar efficacy with an improved adverse event profile.

Jha et al. permitted crossover to the immunosuppressive treatment arm 24 months after randomization to supportive treatment. It is notable that remission rates were lower among patients who switched to immunosuppression as rescue therapy (47%) than among those who were initially randomized to immunosuppression (72%), suggesting that delay in immunosuppressive therapy until evidence of disease progression diminishes efficacy.

Studies reported by du Buf-Vereijken et al. and Hofstra et al. from the Netherlands provide additional insights into the effect of delaying cytotoxic drug therapy for IMN until there is evidence of renal function deterioration. These investigators favor this restrictive treatment policy because it identifies patients at highest risk of progression and avoids unnecessary immunosuppression in patients with a more favorable prognosis. A beneficial effect of this approach in attenuating deterioration of renal function was shown in the case-controlled study of high-risk IMN patients reported by du Buf-Vereijken et al. Renal outcomes of 65 patients treated for 1 year with oral cytoxan and steroids were compared with 24 historical matched control patients. Control patients received either no immunosuppression or treatments that have subsequently proven to be ineffective (prednisone monotherapy, intravenous cyclophosphamide, or both). Patients had an impaired GFR at baseline (median creatinine clearance of 42 ml/min per 1.73 m²) and high-grade proteinuria. Remission of proteinuria was achieved in 86% of 65 patients receiving immunosuppressive therapy (Table 2). At 5 years, a

| Table 1. Immunosuppressive regimens that have been used in treatment of IMN |
|------------------------|------------------|
| **Immunosuppression**  | **Agent**        |
|                        |                  |
| Alkylating agents      |                  |
|                        | Italian Ponticelli protocol |
|                        | Months 1, 3, and 5: 1 g/d intravenous methylprednisolone for 3 consecutive d, followed by oral prednisolone |
|                        | 0.4 mg/kg daily or oral prednisone 0.5 mg/kg daily for 27 d |
|                        | Months 2, 4, and 6: 0.2 mg/kg oral chlorambucil daily for 30 d |
|                        | Modified Ponticelli protocol |
|                        | Months 1, 3, and 5: 1 g/d intravenous methylprednisolone for 3 consecutive d, followed by oral prednisone |
|                        | 0.5 mg/kg daily for 27 d |
|                        | Months 2, 4, and 6: 2–2.5 mg/kg oral cyclophosphamide daily for 30 d |
|                        | Dutch protocol |
|                        | 1.5–2 mg/kg oral cyclophosphamide daily for 12 mo plus 0.5 mg/kg oral prednisone daily or every other day for 6 months and then tapered, plus 1 g/d intravenous methylprednisolone for 3 consecutive days for months 1, 3, and 5 |
|                        | 3.5 mg/kg cyclosporine daily, achieving levels of 125–200 μg/L for a minimum of 6–12 mo, then tapered to lowest possible maintenance dose (± low-dose corticosteroids) |
|                        | 0.05 mg/kg tacrolimus daily achieving levels 7–9 for 6–12 mo, then tapered to lowest possible maintenance dose (± low-dose corticosteroids) |
| Cyclosporine, tacrolimus| 2 g/d MMF for 1 yr ± low-dose corticosteroids |
| MMF                    | 375 mg/m² weekly for four doses |
| Rituximab              | 1 g on days 1 and 15 |
| ACTH                   | 375-mg/m² single doses, titrated to the number of circulating B cells |
|                        | 1 mg tetraoctacosin injected intramuscularly twice weekly for 6–12 mo |
|                        | 80 U corticotropin injected intramuscularly twice weekly for 6–12 mo |
Table 2. Selected studies of alkylating agents in patients with IMN

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Treatment Regimen</th>
<th>Follow-Up</th>
<th>Initial Remission Rate</th>
<th>Relapse Rate (Timing)</th>
<th>Effect on Renal Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 57 (24/42)</td>
<td>PR: 24 (10/42)</td>
<td>Total: 81</td>
</tr>
<tr>
<td>Ponticelli et al. (1989 and 1995)&lt;sup&gt;39,40&lt;/sup&gt;</td>
<td>39</td>
<td>Months 1, 3, and 5: steroids&lt;sup&gt;a&lt;/sup&gt;; months 2, 4, and 6: 0.2 mg/kg chlorambucil daily</td>
<td>Up to 10 yr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 (4/13)</td>
<td>31 (11/36)</td>
<td>(between 6 and 30 mo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 patients (4%) reached ESRD after 36 mo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ponticelli et al. (1998)&lt;sup&gt;43&lt;/sup&gt;</td>
<td>44</td>
<td>Months 1, 3, and 5: steroids&lt;sup&gt;b&lt;/sup&gt;; months 2, 4, and 6: 0.2 mg/kg chlorambucil daily</td>
<td>Median 3 yr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 37 (16/43)</td>
<td>PR: 56 (24/43)</td>
<td>Total: 93</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25 (10/40)</td>
<td>(between 6 and 24 mo)</td>
<td></td>
</tr>
<tr>
<td>Jha et al. (2007)&lt;sup&gt;41&lt;/sup&gt;</td>
<td>47</td>
<td>Months 1, 3, and 5: steroids&lt;sup&gt;c&lt;/sup&gt;; months 2, 4, and 6: 2.5 mg/kg cyclophosphamide daily</td>
<td>Median 11 yr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 32 (15/47)</td>
<td>PR: 40 (19/47)</td>
<td>Total: 72</td>
</tr>
<tr>
<td>du Buf-Vereijken (2004)&lt;sup&gt;34&lt;/sup&gt; (not randomized; matched historical comparison)</td>
<td>65</td>
<td>1.5–2 mg/kg oral cyclophosphamide daily for 12 mo plus steroids&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Median 11 yr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25 (4/16)</td>
<td>(between 6 and 24 mo)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20 (11/56)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hofstra et al. (2010)&lt;sup&gt;42&lt;/sup&gt;</td>
<td>14</td>
<td>1.5 mg/kg oral cyclophosphamide daily for 12 mo plus steroids&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Mean 6 yr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 64 (9/14)</td>
<td>PR: 29 (4/14)</td>
<td>Total: 93</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23 (3/13) (median 36 mo after treatment)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>Late start: 1.5 mg/kg oral cyclophosphamide daily for 12 mo plus steroids&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Mean 6 yr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 67&lt;sup&gt;**&lt;/sup&gt; (8/12)</td>
<td>PR: 25 (3/12)</td>
<td>Total: 92</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>27% (3/11) (median 38 mo after treatment)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are expressed in percentages unless otherwise indicated. CR, complete remission; PR, partial remission; NA, data not available.

<sup>a</sup>Dosages at months 1, 3, and 5: 1 g intravenous methylprednisolone daily for 3 days, followed by 0.4 mg/kg oral prednisolone daily or 0.5 mg/kg prednisone daily for 27 d. Dosage at mo 2, 4, 6: 0.2 mg/kg chlorambucil daily.

<sup>b</sup>Dosages at months 1, 3, and 5: 1 g intravenous methylprednisolone daily.

<sup>c</sup>Dosages at months 1, 3, and 5: 1 g intravenous methylprednisolone daily for 3 days, followed by 0.4 mg/kg oral prednisolone daily for 27 d.

<sup>d</sup>Dosages at months 1, 3, and 5: 1 g intravenous methylprednisolone daily for 3 days, followed by 0.5 mg/kg oral prednisolone (or prednisone) daily.

<sup>e</sup>Dosages at months 1, 3, and 5: 1 g intravenous methylprednisolone daily for 3 days, followed by 0.5 mg/kg oral prednisone every other day for 6 mo and then tapered.

<sup>**</sup>Includes four spontaneous remissions that occurred during the observation period.
renal survival advantage was evident in cytoxan-treated patients compared with controls (86% versus 32%; \( P<0.001 \)). The renal survival of these cytoxan-treated patients at 7 years was 74%, which is somewhat lower than the 10-year renal survival of patients with normal baseline renal function treated with a cytotoxic drug regimen by Ponticelli et al.\textsuperscript{40} (92%).

Hofstra \textit{et al.} recently reported the results of a small but well-designed study comparing early versus late initiation of immunosuppressive treatment.\textsuperscript{42} Patients were randomized to receive oral cyclophosphamide for 12 months plus corticosteroids early after diagnosis (\( n=14 \)) or later if renal function deteriorated (\( n=12 \), defined as an increase of serum creatinine \( \geq 25\% \) reaching a level of \( \geq 135 \text{ umol/L} \) or an increase of serum creatinine \( \geq 50\% \). In the late treatment arm, 67\% of patients ultimately met criteria for immunosuppression after a median of 14 months from randomization. Overall cumulative incidence of remission was similar in both the early and late treatment arms (93\% versus 92\%, respectively) but earlier treatment resulted in more rapid onset of remission. Relapse rates were similar. At final follow-up (mean 72 months), there were no differences in clinical status, proteinuria, or renal function in either group, with the latter observation indicating that immunosuppressive treatment led to an improvement in renal function in the late treatment arm (because those patients started out with a lower average GFR). The good overall outcomes do provide reassurance that delaying therapy is justified in some patients. By delaying treatment, 33\% of patients avoided unnecessary exposure to immunosuppression. However, delayed treatment was associated with more frequent and severe side effects and more hospitalizations. An individualized approach that considers age, pre-existing comorbidities, and risk of treatment versus risk of complications of the nephrotic syndrome is critical when deciding on therapy.

Despite the favorable results with alkylating agents, there is reluctance to prescribe them due to the short-term and potential long-term adverse effects. Short-term effects include myelosuppression, especially leucopenia infections, hemorrhagic cystitis, and gastrointestinal problems such as peptic ulcers, nausea, anorexia, and liver dysfunction. Risk of infertility remains a concern for patients in childbearing years. Cancer risk remains a long-term worry, particularly since the cumulative dosage of cyclophosphamide increases if repeat courses are needed after relapse. The Ponticelli regimen entails 3 months of cyclophosphamide (2 mg/kg daily), which is a cumulative dose of approximately 13 g in a 70-kg patient. The 12-month regimen\textsuperscript{34} (using 1.5 mg/kg daily) represents a cumulative dose of approximately 40 g in a 70-kg patient. Several studies have reported threshold values for cumulative doses of cyclophosphamide, above which is associated with increased risk of malignancies such as bladder cancer, skin cancer, and lymphoproliferative disorders. Older studies report an increased risk of malignancy with cumulative doses \( >50 \text{ g} \),\textsuperscript{45,46} whereas more recent studies suggest that exposure to lower cumulative dosages may also pose an increased risk.\textsuperscript{47}

\textbf{CNIs}

Cyclosporine is an established option for treatment of IMN patients at moderate or high risk of disease progression.\textsuperscript{48} Tacrolimus, another CNI, is an alternative.\textsuperscript{49,50} Cumulative data indicate that CNIs are effective in inducing a remission of proteinuria in up to 80\% of patients (Table 3).\textsuperscript{49–52} CNIs show favorable responses in patients who have been unresponsive to other immunosuppressants, including alkylating agents.\textsuperscript{51–54} In a recent randomized controlled trial in which all patients had previously failed the Ponticelli protocol, treatment with cyclosporine for 2 years (plus low-dose prednisone) led to remissions in 80\% of patients and stabilization of renal function.\textsuperscript{52}

The antiproteinuric effect of CNIs is typically evident early. Generally, if some response in proteinuria is not present by 3 months (provided adequate drug levels are achieved), it is unlikely that a significant response will occur later. However, time to maximum reduction of proteinuria takes longer. Although optimal duration of therapy has not been established, extended therapy for at least a year is recommended for patients who show an initial response to these agents, because the number of remissions and proportion of complete remissions increases with duration of treatment.\textsuperscript{53}

The majority of complete remissions with CNIs occur after at least 6 months of therapy and the number increases as treatment continues for \( >12 \) months. This concept is supported by several studies.\textsuperscript{49,52,53,55} A prospective study by Naumovic \textit{et al.} recently showed that a prolonged course of cyclosporine for 24 months led to a steady increase in cumulative remission rates from 50\% at 6 months to 80\% by 18 months, and complete remissions increased from 0 at 6 months to 40\% by 18 months.\textsuperscript{52} Mean time to partial remission was 9.7 months (range, 3–18 months), and mean time to complete remission was 15 months (range, 9–18 months). These outcomes are consistent with the results of earlier studies reported by Cattran \textit{et al.} and Praga \textit{et al.} (Table 3). Cattran \textit{et al.} found that a 6-month course of cyclosporine led to complete remissions in only 7\% of his patients,\textsuperscript{51} whereas Praga \textit{et al.} observed complete remissions in 32\% of patients after 18 months of tacrolimus treatment.\textsuperscript{49}

Relapse upon drug withdrawal is a well recognized problem with CNIs, occurring in 13\% to almost 50\% of patients within 1 year of drug withdrawal.\textsuperscript{49} In the above-mentioned study by Praga \textit{et al.}, 47\% of patients randomized to tacrolimus relapsed within an average of 4 months after discontinuation of therapy such that by final follow-up, the number of remissions in the tacrolimus arm was not markedly different from the placebo arm.\textsuperscript{49} These data provide additional justification for long-term treatment. Maintenance therapy with low-dose cyclosporine (1.4–1.5 mg/kg daily; trough levels \( >100 \text{ ng/ml} \)), possibly in conjunction with low-dose steroids (0.1 mg/kg daily), may help to reduce the likelihood of relapses\textsuperscript{55}; however, this practice has not been formally tested in randomized controlled trials.

The role of CNIs in attenuating a decline in renal function and the long-term...
<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Treatment (Total Duration)</th>
<th>Follow-Up (mo)</th>
<th>Remissions</th>
<th>Relapse Rate (n) [Time to Relapse]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catran et al. (2001)</td>
<td>28</td>
<td>3.5 mg/kg cyclosporine daily (26 wk); target trough 125–225 μg/ml for 26 wk, then tapered for 4 wk plus 0.15 mg/kg prednisone daily</td>
<td>Up to 19</td>
<td>CR (2/28)</td>
<td>72 (19/28) 75 (2/28) PR (11/28) Total (46)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo plus 0.15 mg/kg prednisone daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naumovic et al. (2011)</td>
<td>10</td>
<td>3 mg/kg cyclosporine daily for 6 mo, then adjusted to achieve trough levels of 80–100 ng/ml (24 mo) plus 0.5 mg/kg prednisone daily for 8 wk, then tapered</td>
<td>36</td>
<td>0 (1/13)</td>
<td>50 (5/10) 50 (1/10) 40 (4/10) 50 (4/10) 80 (2/5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.5–2 mg/kg azathioprine daily for 6 mo, then 50 mg daily (24 mo) plus 0.5 mg/kg prednisone daily for 8 wk, then tapered</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Praga et al. (2007)</td>
<td>25</td>
<td>0.05 mg/kg tacrolimus daily for 12 mo (trough level 5–8 ng/ml), then tapered over 6 mo (18 mo)</td>
<td>Up to 30</td>
<td>12 (23/25)</td>
<td>44 (11/25) 56 (6/25) 48 (12/25) Total (72)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Conservative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen et al. (2010)</td>
<td>39</td>
<td>0.1 mg/kg tacrolimus daily for 6 mo; target trough 5–10 ng/ml, then adjusted for trough 2–5 ng/ml (9 mo) plus 1 mg/kg prednisone daily for 4 wk, then tapered over 8 mo</td>
<td>12</td>
<td>28 (11/39)</td>
<td>56 (22/39) 85 (4/13) NA NA 79 (13/23) a 26 (5/23)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 mg/d cytoxan (4 mo) plus 1 mg/kg prednisone daily for 4 wk, then tapered over 8 mo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are expressed in percentages unless otherwise indicated. CR, complete remission; PR, partial remission; NA, data not available.

*Remission rates reported at 18 mo (24-mo remission status not provided).
BRIEF REVIEW

Effect on renal survival in IMN are less clear due to lack of longitudinal studies. Cattran et al. reported reduced rates of deterioration of renal function with cyclosporine in one small study of high-risk patients. In a study design similar to that used by du Buf-Vereijken et al., 65 patients with IMN were initially followed conservatively for 12 months. Only patients with clear evidence of declining renal function and persistent nephrotic-range proteinuria during the observation period were randomized to receive treatment with cyclosporine for 12 months or placebo. Of 65 patients, 23 (36%) met criteria for randomization. Compared with placebo, cyclosporine-treated patients demonstrated significantly reduced proteinuria (halving of proteinuria in 50% of treated patients versus no improvement in placebo patients) and slower rates of decline in kidney function as measured by change in the slope of creatinine clearance. These improvements were sustained in 75% of the patients for up to 2 years post-treatment. Fewer patients in the treated group progressed to end stage (11% versus 50%, respectively). In contrast, a controlled trial by the Cyclosporine in Membranous Nephropathy Study Group failed to demonstrate any long-term benefits of cyclosporine when used in patients with deteriorating renal function. In light of the nephrotoxic potential of calcineurin inhibitors, caution and close monitoring of blood drug levels and renal function are advised if CNIs are initiated in patients with an important group of patients.

No prospective randomized head-to-head comparisons of cyclosporine (or tacrolimus) to standard regimens of alkylating agents have been conducted. A retrospective study by Goumenos et al. attempted to address this issue by comparing the outcomes of patients who were treated with a 6-month Ponticelli protocol (steroids plus chlorambucil or cyclophosphamide; n=31) with those treated with cyclosporine for 2 years plus steroids (n=46). The use of different therapeutic regimens in the two groups reflects institutional treatment preferences over a 10-year period. Baseline characteristics of the groups were similar. More remissions occurred among the cyclosporine-treated patients than among those receiving alkylating agents (85% versus 55%; P<0.004). Relapses tended to occur more often in the cyclosporine-treated group but the differences were not significant (41% versus 29%, respectively). During a mean follow-up of 48±36 months there were no differences in rates of doubling of serum creatinine between treatment groups (26% versus 23%, respectively) or requirement for renal replacement therapy. However, the design and retrospective nature of the study preclude definitive comparisons of these therapies for IMN.

A recent multicenter randomized controlled trial from China compared efficacy of tacrolimus with an abbreviated course of cytoxan in 73 patients with IMN. Patients were randomized to receive tacrolimus for 9 months or 4 months of daily oral cytoxan (100 mg/d). Both groups received oral prednisone. Cumulative remission rates at 6 months were greater in the tacrolimus arm than the cytoxan arm (85% versus 65%, P<0.05); however, remission rates were comparable by 12 months. Relapse rates between the two groups were similar (18% versus 23%), leading the authors to conclude that short-term efficacy of tacrolimus plus steroids might be better than cyclophosphamide plus steroids. Several issues limit the conclusions that can be drawn from this study. Tacrolimus was not compared with one of the standard cytoxan-containing regimens. Follow-up was very short, which may underestimate true relapse rates. Last, there was inconsistent use of ACE inhibitors and ARBs, which favored the tacrolimus group.

Currently, there is a three-arm randomized controlled trial in progress in the United Kingdom that compares supportive therapy versus 12 months of cyclosporine versus 6 months of alternating prednisolone/chlorambucil in patients with progressive IMN. The results of this trial are eagerly awaited and should provide information regarding this important group of patients.

Rituximab

Of the newer agents being explored for IMN, rituximab has emerged as the most likely candidate to be incorporated into treatment guidelines. Although it has yet to be tested in randomized controlled trials and there is a lack of longitudinal data, important groundwork has been laid since its first reported use for IMN in 2002. Most of the reported experiences with rituximab are from uncontrolled pilot trials or case series from two centers in Bergamo, Italy, and the Mayo Clinic in the United States.

The following treatment protocols have been tried for IMN (Table 1): four weekly doses of 375 mg/m², which is standard dosing for treatment of lymphoma; two 1000-mg doses given biweekly, which is standard for rheumatoid arthritis; and a B cell–driven protocol in which dosing is titrated to the number of circulating B cells. The pharmacokinetics of rituximab in nephrotic patients differ from that in nonproteinuric patients treated with identical protocols, prompting interesting questions about the optimal dosing regimen for IMN. Compared with nonproteinuric patients, rituximab levels are lower and recovery of CD20-expressing B cells typically occurs earlier in nephrotic patients. However, among nephrotic patients with IMN, the four-dose lymphoma and two-dose arthritis regimens seem to have similar efficacy despite faster B cell recovery after the two-dose regimen.

Consistent with these conclusions, a recent retrospective analysis of banked serum samples showed no detectable differences in the progressive reduction of anti-PLA₂R levels between the two dosing regimens.

Regardless of the regimen administered, proteinuria tends to decline slowly and remissions may occur up to 2 years after treatment (Table 4). Interestingly, Beck et al. showed that after administration of rituximab, the median time to reach undetectable anti-PLA₂R levels was 9 months (range, 1–18 months). This may explain the delay in remissions, because the reduction in antibody levels seems to precede the decline in proteinuria by months.
It is interesting to note that remissions continue to occur well after the end of therapy with rituximab or alkylating agents; complete remissions can be seen 12 months after the completion of these interventions. This is in contrast to what is observed after cyclosporine or tacrolimus, in which typically no additional remissions occur once treatment stops.

Relapse rates after rituximab therapy are difficult to estimate given the limited longitudinal data. There are two published studies (n = 31) that followed patients for up to 24 months and relapses were infrequent (6% and 13%, respectively). It is hoped that forthcoming studies with extended follow-up will provide much needed information. Such data may inform decisions regarding role and timing of redosing.

Currently, there are no established guidelines for the use of rituximab, regardless of clinical status. Remuzzi et al. have reduced rituximab dosing at 6 months or other predefined intervals; however, it is not clear if this will lead to a reduction in relapse rates. Further studies are needed to determine the optimal timing and dosing of rituximab.

Table 4. Selected studies of rituximab for IMN and evolution of remissions over time

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Treatment Regimen</th>
<th>Remissions (CR) 6 mo</th>
<th>PR 6 mo</th>
<th>Total 6 mo</th>
<th>Remissions (CR) 12 mo</th>
<th>PR 12 mo</th>
<th>Total 12 mo</th>
<th>Remissions (CR) 24 mo</th>
<th>PR 24 mo</th>
<th>Total 24 mo</th>
<th>Relapse Rate (n) [Time to Relapse]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remuzzi et al. (2002)</td>
<td>8</td>
<td>Four doses of 375 mg/m² per wk</td>
<td>0</td>
<td>63 (5/8)</td>
<td>63</td>
<td>0</td>
<td>63 (5/8)</td>
<td>63</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>13 (1/8) [within 24 mo]</td>
</tr>
<tr>
<td>and Ruggenenti et al. (2003)</td>
<td>8</td>
<td>375 mg/m² per wk for 4 wk or 375 mg/m² per 1 wk; redosed when $\geq 5 \times 10^7$ B cells/mm³</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>18 (2/11)</td>
<td>45 (5/11)</td>
<td>63</td>
<td>27 (3/11)</td>
<td>45 (5/11)</td>
<td>63</td>
<td>14 (1/7) [within 24 mo]</td>
</tr>
<tr>
<td>Cravedi et al. (2011)</td>
<td>22b</td>
<td>Two 1-g doses on days 1 and 15; repeated at 6 mo if proteinuria $&gt; 3 \times 10^3$ g/d and CD19+B cells $&gt; 15 \times 10^6$/m³</td>
<td>0</td>
<td>29 (4/14)</td>
<td>29</td>
<td>14 (2/14)</td>
<td>43 (6/14)</td>
<td>57</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Fervenza et al. (2008)</td>
<td>15</td>
<td>Four doses of 375 mg/m² per week; repeated at 6 mo</td>
<td>0</td>
<td>40 (8/20)</td>
<td>40</td>
<td>0</td>
<td>50 (10/20)</td>
<td>50</td>
<td>20 (4/20)</td>
<td>60 (12/20)</td>
<td>80</td>
<td>6 (1/16)</td>
</tr>
<tr>
<td>Fervenza et al. (2010)</td>
<td>20</td>
<td>Four doses of 375 mg/m² per week; repeated at 6 mo</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>18 (2/11)</td>
<td>45 (5/11)</td>
<td>63</td>
<td>27 (3/11)</td>
<td>45 (5/11)</td>
<td>63</td>
<td>14 (1/7) [within 24 mo]</td>
</tr>
</tbody>
</table>

Data are expressed in percentages unless otherwise indicated. CR, complete remission; PR, partial remission; NA, data not available.

a Remission status was standardized for ease of comparison. CR defined as proteinuria $< 0.3 \times 10^3$ g/d; PR defined as proteinuria $< 10^3$ g/d and a 50% reduction from peak value.

b Eleven patients were given rituximab as first-line therapy, and 11 patients were given rituximab as second-line therapy.
syndrome. Combining rituximab with an abbreviated course of another agent that has a quicker onset of antiproteinuric effects (CNIs) is an approach that we are currently investigating.

We do need to have a balanced perspective regarding the toxicity profile of rituximab. Although acute infusion reactions are often mild and manageable (e.g., fever, chills, pruritus, and skin rash), more severe and potentially fatal reactions (e.g., acute respiratory distress syndrome, bronchospasms, angioedema, shock and myocardial infarction) as well as potentially fatal mucocutaneous reactions (e.g., Stevens-Johnson syndrome and toxic epidermal necrolysis) can occur. Rare cases of the devastating demyelinating central nervous system disease, progressive multifocal leukoencephalopathy, have also been reported, although typically when administered as part of multidrug immunosuppressive regimens. Finally, the long-term safety profile of rituximab in glomerular diseases is largely unknown, particularly if repeated courses are needed.

Controlled prospective trials are needed to compare the efficacy and toxicity of rituximab with CNIs and cytotoxic drugs. More data are needed to clarify the role of rituximab in patients with impaired or declining renal function and the effects of rituximab on hard endpoints such as dialysis and death. A randomized controlled trial comparing rituximab with cyclosporine is underway and hopefully will provide much needed answers.

**MMF**

Encouraging results from early, uncontrolled series published almost a decade ago indicated a potential role of MMF in the management of high-risk patients with IMN. Subsequent studies have produced mixed results (Table 5). A multicenter randomized controlled trial from France reported cumulative remission rates after 1 year of MMF that were no different from conservative therapy (approximately 40%). Two other studies suggested that treatment with MMF had similar efficacy as a regimen consisting of alkylating agents plus steroids. A multicenter trial from China by Chan et al. randomized 20 treatment-naive, newly diagnosed nephrotic patients to undergo 6 months of treatment with MMF (2 g/d) plus prednisolone or with a regimen of chlorambucil alternating with corticosteroids. The treatment arms achieved similar remission rates (approximately 65%) at 15 months and experienced few relapses. To note, the study was not powered to demonstrate equivalency or noninferiority, follow-up was too short to evaluate relapse or renal survival outcomes, and only patients with a favorable risk profile were enrolled. Furthermore, only Asian patients were included. On the basis of studies of other primary glomerulopathies, Asian ethnicity may be associated with a relatively favorable prognosis and increased responsiveness to certain immunosuppressive regimens.

A trial from the Netherlands compared outcomes of 32 IMN patients treated with 1 year of MMF plus corticosteroids with historical matched controls treated with oral cyclophosphamide plus corticosteroids for 1 year. Patients were considered at high risk for progressive disease with reduced GFR at baseline (median approximately 40 mL/min) and high-grade proteinuria. Two groups achieved similar initial remission rates (approximately 70%). Renal function stabilized or improved in the majority of patients during the year of therapy with MMF. However, the post-treatment relapse rate was considerably higher in the MMF group such that by the end of follow-up (median 23 months), patients in the MMF arm were less likely to be in remission than those in the cytoxan arm (44% versus 75%; P=0.02).

Post-treatment relapse is problematic. In the trial by Branten et al., 57% of patients relapsed within 2 years and some relapses occurred during active treatment. Of interest, relapse is also a concern after treatment with the related older antimetabolite, azathioprine. A recent study showed that 12 months of azathioprine induced remissions in a large percentage of patients who had previously been refractory to

### Table 5. Selected studies using MMF in IMN

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Type</th>
<th>n</th>
<th>Treatment Regimen (Duration)</th>
<th>Follow-Up (mo)</th>
<th>Remissions (Initial)</th>
<th>Relapse Rate (n) [Time to Relapse]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chan et al. (2007)</td>
<td>RCT</td>
<td>11</td>
<td>2 g/d MMF (6 mo) plus prednisone (0.8 mg/kg daily tapered over 6 mo)</td>
<td>Up to 15</td>
<td>27 (3/11) 36 4/11 63</td>
<td>29 (2/7) [within 2–8 mo after achieving remission]</td>
</tr>
<tr>
<td>Branten et al. (2007)</td>
<td>Historical matched comparison</td>
<td>9</td>
<td>Modified Ponticelli protocol a</td>
<td>33 (3/9) 33 3/9 66</td>
<td>17 (1/6)</td>
<td></td>
</tr>
<tr>
<td>Branten et al. (2007)</td>
<td>Historical matched comparison</td>
<td>32</td>
<td>2 g/d MMF (12 mo) plus steroids b</td>
<td>Median 23</td>
<td>NR 66 (21/32) 66</td>
<td>57 (12/21) [within 2 yr]</td>
</tr>
<tr>
<td>Dussol et al. (2008)</td>
<td>RCT</td>
<td>19</td>
<td>2 g/d MMF (12 mo)</td>
<td>Up to 12</td>
<td>5 (1/19) 32 (6/19) 37</td>
<td>NR</td>
</tr>
</tbody>
</table>

Data are expressed in percentages unless otherwise indicated. CR, complete remission; PR, partial remission; RCT, randomized controlled trial. NR, not reported.

aSteroid dosage during mo 1, 3, and 5: 1 g/d intravenous methylprednisolone for 3 d, 0.4 mg/kg oral prednisolone daily for 21 d, and then 0.2 mg/kg daily for 6 d; mo 2, 4, and 6: 0.2 mg/kg oral chlorambucil daily.

bDosage of 0.5 mg/kg oral prednisone every other day for 6 mo and then tapered, plus intravenous methylprednisolone 1 g/d for 3 days during months 1, 3, and 5.
the Ponticelli protocol. However, within 6 months of azathioprine withdrawal, 33% relapsed.

Although the initial enthusiasm regarding MMF has quieted, a place for MMF in treatment of IMN cannot be discounted at this point. However, until more data become available, it is difficult to recommend MMF as initial therapy. It may be a reasonable option for patients in whom toxicity of alkylating agents and high-dose steroids are a concern or when significant azotemia prohibits use of CNIs (Figure 1). MMF has been used with some success as rescue therapy in patients resistant to other immunosuppression and has also been tried as adjunctive or maintenance therapy to avoid prolonged exposure to CNIs71; however, the evidence is too limited to recommend routine use of MMF for these indications. Extended duration of treatment (>12 months), and possibly the addition of oral corticosteroids, may be necessary to achieve greater antiproteinuric effects or to prevent relapse. The optimal target dosing of MMF for IMN is not known because the kinetics of MMF in patients with hypoalbuminemia and nephrotic syndrome are not well defined. It is possible that higher drug doses are needed to reach the therapeutic window.

ACTH

ACTH is one of the newer agents being explored for treatment of IMN but it certainly is not a new drug. Historically, ACTH was used decades ago to treat nephrotic syndrome as well as a variety of inflammatory and autoimmune diseases. However, this parenterally administered drug fell out of favor when the greater clinical benefits of oral steroids were recognized. Its use was recently resurrected after Berg et al. in Sweden observed reduction in proteinuria when ACTH was administered for lipid-lowering purposes in patients with IMN.82

Initial experiences with ACTH have been in Europe using ACTH tetracosactide, a synthetic, depot formulation (tetracosactrin; Novartis Pharmaceuticals, Basel, Switzerland). The data are conflicting. Several small case series reported reduction of proteinuria in IMN patients, many of whom were refractory to other therapies.83–86 A small multicenter randomized control trial of 32 patients by Ponticelli et al. compared efficacy of 6 months of alkylating agents alternating with corticosteroids to tetracosactrin intramuscular injections for 1 year (1 mg twice weekly).87 There were no significant differences in cumulative remission rates between the treatment arms initially.

---

**Figure 1.** Current consensus guidelines for treatment of IMN, adapted from Cattran et al. Possible positions of MMF and rituximab in treatment scheme based on available data (but not currently in guidelines). SAE, severe adverse event.
(93% versus 87%, respectively) or at final follow-up of 21 months (75% total versus 87%, respectively). However, it is notable that these patients were treatment naive, with preserved kidney function and low to modest degrees of proteinuria (5–6 g/d)—all of which may lead to an overly optimistic view of remission rates. Outcomes were not as favorable in a recent prospective study from the Netherlands in which tetracosactrin was administered to high-risk IMN patients. Patients were considered at high risk for progression based on elevated urinary β2 microglobulin levels and high-grade proteinuria. After 9 months of treatment, only 44% of patients achieved remission and relapse rates were high (43%). Other investigators have reported similarly high relapse rates after drug discontinuation, particularly after short courses of therapy.

A different formulation of ACTH, a naturally purified gel, is available in the United States (corticotropin; Questcor Pharmaceuticals Inc, Anaheim Hills, CA). In a retrospective study of corticotropin in proteinuric glomerular diseases, 9 of 11 (82%) patients with IMN achieved a remission (three complete; six partial). The complete remissions occurred in patients with relatively low levels of baseline proteinuria (2.6–4.8 g/d). Interpretations of the data are limited due to the uncontrolled nature of the study, the variable dosing regimens used, a possible carry-over effect from previously administered immunosuppression, and short follow-up (beyond the active treatment period).

The mechanisms by which ACTH exerts its antiproteinuric effect are not well understood. Multiple mechanisms likely contribute and may involve both immune-mediated and immune-independent mechanisms. The effects are not thought to be mediated by induction of endogenous cortisol from the adrenal glands because administration of corticosteroids as monotherapy has not been effective in the context of a clinical research study. Ongoing studies of pathogenic mechanisms and innovative treatments will refine our approach to the treatment of membranous nephropathy.

**ACKNOWLEDGMENT**

This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

**DISCLOSURES**

None.

**REFERENCES**


64. Chan TM, Lin AW, Tang SC, Qian JQ, Lam MF, Ho YY, Tse KC, Chan KW, Lai KN, Tang CS: Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with...


